Literature DB >> 35513493

Tumour immunotherapy: lessons from predator-prey theory.

Phineas T Hamilton1, Bradley R Anholt2, Brad H Nelson3,4,5.   

Abstract

With the burgeoning use of immune-based treatments for cancer, never has there been a greater need to understand the tumour microenvironment within which immune cells function and how it can be perturbed to inhibit tumour growth. Yet, current challenges in identifying optimal combinations of immunotherapies and engineering new cell-based therapies highlight the limitations of conventional paradigms for the study of the tumour microenvironment. Ecology has a rich history of studying predator-prey dynamics to discern factors that drive prey to extinction. Here, we describe the basic tenets of predator-prey theory as applied to 'predation' by immune cells and the 'extinction' of cancer cells. Our synthesis reveals fundamental mechanisms by which antitumour immunity might fail in sometimes counterintuitive ways and provides a fresh yet evidence-based framework to better understand and therapeutically target the immune-cancer interface.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35513493     DOI: 10.1038/s41577-022-00719-y

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  121 in total

1.  A change of strategy in the war on cancer.

Authors:  Robert A Gatenby
Journal:  Nature       Date:  2009-05-28       Impact factor: 49.962

2.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

3.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

4.  Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

Authors:  Nasser H Hanna; Bryan J Schneider; Sarah Temin; Sherman Baker; Julie Brahmer; Peter M Ellis; Laurie E Gaspar; Rami Y Haddad; Paul J Hesketh; Dharamvir Jain; Ishmael Jaiyesimi; David H Johnson; Natasha B Leighl; Tanyanika Phillips; Gregory J Riely; Andrew G Robinson; Rafael Rosell; Joan H Schiller; Navneet Singh; David R Spigel; Janis O Stabler; Joan Tashbar; Gregory Masters
Journal:  J Clin Oncol       Date:  2020-01-28       Impact factor: 44.544

Review 5.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Authors:  Jonathan J Havel; Diego Chowell; Timothy A Chan
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

6.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

7.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

8.  Systemic Therapy for Melanoma: ASCO Guideline.

Authors:  Rahul Seth; Hans Messersmith; Varinder Kaur; John M Kirkwood; Ragini Kudchadkar; Jennifer Leigh McQuade; Anthony Provenzano; Umang Swami; Jeffrey Weber; Krishna C Alluri; Sanjiv Agarwala; Paolo A Ascierto; Michael B Atkins; Nancy Davis; Marc S Ernstoff; Mark B Faries; Jason S Gold; Samantha Guild; David E Gyorki; Nikhil I Khushalani; Michael O Meyers; Caroline Robert; Mario Santinami; Amikar Sehdev; Vernon K Sondak; Gilliosa Spurrier; Katy K Tsai; Alexander van Akkooi; Pauline Funchain
Journal:  J Clin Oncol       Date:  2020-03-31       Impact factor: 44.544

9.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jingsong Zhang; Jessica J Cunningham; Joel S Brown; Robert A Gatenby
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919

Review 10.  Classifying the evolutionary and ecological features of neoplasms.

Authors:  Carlo C Maley; Athena Aktipis; Trevor A Graham; Andrea Sottoriva; Amy M Boddy; Michalina Janiszewska; Ariosto S Silva; Marco Gerlinger; Yinyin Yuan; Kenneth J Pienta; Karen S Anderson; Robert Gatenby; Charles Swanton; David Posada; Chung-I Wu; Joshua D Schiffman; E Shelley Hwang; Kornelia Polyak; Alexander R A Anderson; Joel S Brown; Mel Greaves; Darryl Shibata
Journal:  Nat Rev Cancer       Date:  2017-09-15       Impact factor: 60.716

View more
  2 in total

Review 1.  Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.

Authors:  Sara R Martins-Neves; Gabriela Sampaio-Ribeiro; Célia M F Gomes
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

2.  Comparison of Predator-Prey Model and Hawk-Dove Game for Modelling Leukemia.

Authors:  Mariam Sultana; Fareeha Sami Khan; M Khalid; Areej A Al-Moneef; Ali Hasan Ali; Omar Bazighifan
Journal:  Comput Intell Neurosci       Date:  2022-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.